Gastroesophageal reflux disease (GERD), gastro-oesophageal reflux disease (GORD), gastric reflux disease, or acid reflux disease is a chronic symptom of mucosal damage caused by stomach acid coming up from the stomach into the esophagus.
GERD is usually caused by changes in the barrier between the stomach and the esophagus, including abnormal relaxation of the lower esophageal sphincter, which normally holds the top of the stomach closed; impaired expulsion of gastric reflux from the esophagus, or a hiatal hernia. These changes may be permanent or temporary ("transient").
Another kind of acid reflux, which causes respiratory and laryngeal signs and symptoms, is called laryngopharyngeal reflux (LPR) or "extraesophageal reflux disease" (EERD). Unlike GERD, LPR is unlikely to produce heartburn, and is sometimes called silent reflux.
Signs and symptoms
The most-common symptoms of GERD are:
Less-common symptoms include:
GERD sometimes causes injury of the esophagus. These injuries may include:
Several other atypical symptoms are associated with GERD, but there is good evidence for causation only when they are accompanied by esophageal injury. These symptoms are:
Some people have proposed that symptoms such as sinusitis, recurrent ear infections, and idiopathic pulmonary fibrosis are due to GERD; however, a causative role has not been established.
GERD may be difficult to detect in infants and children, since they cannot describe what they are feeling and indicators must be observed. Symptoms may vary from typical adult symptoms. GERD in children may cause repeated vomiting, effortless spitting up, coughing, and other respiratory problems such as wheezing. Inconsolable crying, refusing food, crying for food and then pulling off the bottle or breast only to cry for it again, failure to gain adequate weight, bad breath, and belching or burping are also common. Children may have one symptom or many; no single symptom is universal in all children with GERD.
It is estimated that of the approximately 4 million babies born in the U.S. each year, up to 35% of them may have difficulties with reflux in the first few months of their life, known as spitting up. One theory for this is the "4th trimester theory" which notes that most animals are born with significant mobility, but humans are relatively helpless at birth, and suggests that there may have once been a fourth trimester, but that children began to be born earlier, evolutionarily, to accommodate the development of larger heads and brains and allow them to pass through the birth canal  and this leaves them with partially undeveloped digestive systems.
Most children will outgrow their reflux by their first birthday. However, a small but significant number of them will not outgrow the condition. This is particularly true where there is a family history of GERD present.
GERD may lead to Barrett's esophagus, a type of intestinal metaplasia, which is in turn a precursor condition for carcinoma. The risk of progression from Barrett's to dysplasia is uncertain but is estimated at about 20% of cases. Due to the risk of chronic heartburn progressing to Barrett's, EGD every five years is recommended for patients with chronic heartburn, or who take drugs for chronic GERD.
image of peptic stricture, or narrowing of the esophagus
near the junction with the stomach
. This is a complication of chronic gastroesophageal reflux disease and can be a cause of dysphagia
or difficulty swallowing.
X-ray of the abdomen and chest in a patient with a gastrostomy. Radiocontrast was injected into the stomach and quickly seen migrating upwards through the entire esophagus. The patient had severe reflux esophagitis (Los Angeles grade D).
A detailed historical knowledge is vital for an accurate diagnosis. Useful investigations may include ambulatory Esophageal pH Monitoring, barium swallow X-rays, esophageal manometry, and Esophagogastroduodenoscopy (EGD).
The current gold standard for diagnosis of GERD is esophageal pH monitoring. It is the most objective test to diagnose the reflux disease and it also allows to monitor GERD patients in regards of their response to medical or surgical treatment. One practice for diagnosis of GERD is a short-term treatment with proton pump inhibitors, with improvement in symptoms suggesting a positive diagnosis. According to a systematic review, short-term treatment with proton pump inhibitors may help predict abnormal 24-hr pH monitoring results among patients with symptoms suggestive of GERD. In this study, the positive likelihood ratio of a symptomatic response detecting GERD ranged from 1.63 to 1.87, with sensitivity of 0.78 though specificity was only 0.54.
In general, an EGD is done when the patient either does not respond well to treatment or has alarm symptoms including dysphagia, anemia, blood in the stool (detected chemically), wheezing, weight loss, or voice changes. Some physicians advocate either once-in-a-lifetime or 5/10-yearly endoscopy for patients with longstanding GERD, to evaluate the possible presence of dysplasia or Barrett's esophagus, a precursor lesion for esophageal adenocarcinoma.
Esophagogastroduodenoscopy (EGD) (a form of endoscopy) involves insertion of a thin scope through the mouth and throat into the esophagus and stomach (often while the patient is sedated) in order to assess the internal surfaces of the esophagus, stomach, and duodenum.
Biopsies can be performed during gastroscopy and these may show:
- Edema and basal hyperplasia (non-specific inflammatory changes)
- Lymphocytic inflammation (non-specific)
- Neutrophilic inflammation (usually due to reflux or Helicobacter gastritis)
- Eosinophilic inflammation (usually due to reflux). The presence of intraepithelial eosinophils may suggest a diagnosis of eosinophilic esophagitis (EE)if eosinophils are present in high enough numbers. Less than 20 eosinophils per high-power microscopic field in the distal esophagus, in the presence of other histologic features of GERD, is more consistent with GERD than EE.
- Goblet cell intestinal metaplasia or Barretts esophagus
- Elongation of the papillae
- Thinning of the squamous cell layer
- Dysplasia or pre-cancer
Reflux changes may be non-erosive in nature, leading to the entity "non-erosive reflux disease".
GERD is caused by a failure of the cardia. In healthy patients, the "Angle of His"—the angle at which the esophagus enters the stomach—creates a valve that prevents duodenal bile, enzymes, and stomach acid from traveling back into the esophagus where they can cause burning and inflammation of sensitive esophageal tissue.
Factors that can contribute to GERD:
- Hiatal hernia, which increases the likelihood of GERD due to mechanical and motility factors.
- Obesity: increasing body mass index is associated with more severe GERD. In a large series of 2000 patients with symptomatic reflux disease, it has been shown that 13% of changes in esophageal acid exposure is attributable to changes in body mass index.
- Zollinger-Ellison syndrome, which can be present with increased gastric acidity due to gastrin production.
- Hypercalcemia, which can increase gastrin production, leading to increased acidity.
- Scleroderma and systemic sclerosis, which can feature esophageal dysmotility.
- The use of medicines such as prednisolone.
- Visceroptosis or Glénard syndrome, in which the stomach has sunk in the abdomen upsetting the motility and acid secretion of the stomach.
GERD has been linked to a variety of respiratory and laryngeal complaints such as laryngitis, chronic cough, pulmonary fibrosis, earache, and asthma, even when not clinically apparent. These atypical manifestations of GERD is commonly referred to as laryngopharyngeal reflux or as extraesophageal reflux disease (EERD).
Factors that have been linked with GERD, but not conclusively:
In 1999, a review of existing studies found that, on average, 40% of GERD patients also had H. pylori infection. The eradication of H. pylori can lead to an increase in acid secretion, leading to the question of whether H. pylori-infected GERD patients are any different than non-infected GERD patients. A double-blind study, reported in 2004, found no clinically significant difference between these two types of patients with regard to the subjective or objective measures of disease severity.
GERD is largely preventable through changes in lifestyle, which are also used as treatment (see below).
- Sleep on the left side, or with your upper body raised.
- Relief is often found by raising the head of the bed to 30 degrees, raising the upper body with pillows, or sleeping sitting up. The upper body must be raised, not just the head; pillows that only raise the head do little for heartburn and put strain on the neck. Sleeping on the left side also keeps gravity working for you, keeping your stomach below your esophagus.
- Eat smaller meals.
- Eating a big meal causes excess stomach acid production, so attacks can be minimized by eating smaller meals. It is also important to avoid eating shortly before bedtime.
- Lose weight.
- Gaining even a few pounds increases your risk of heartburn. Exactly why isn't clear, but the leading theory is that more body fat puts more pressure on the stomach, which can cause highly acidic stomach contents to reflux to the lower esophageal sphincter. For the same reason, tight clothing around the abdomen can also increase the risk of heartburn.
- Avoid acidic and rich foods.
- Though less well supported by evidence, a sufferer may benefit from avoiding foods that trigger their symptoms. These commonly include acidic fruit or juices, fatty foods, coffee, tea, onions, peppermint, chocolate, especially shortly before bedtime.
- Avoid consuming irritating substances that can trigger heartburn symptoms such as caffeine, nicotine, and alcohol
Three types of treatments exist for GERD. These include lifestyle modifications, medications, and surgery.
Certain foods and lifestyle are considered to promote gastroesophageal reflux, but a 2006 review suggested that evidence for most dietary interventions is anecdotal; only weight loss and elevating the head of the bed were supported by evidence. A subsequent randomized crossover study showed benefit by avoiding eating two hours before bedtime.
The following may exacerbate the symptoms of GERD:
- Antacids based on calcium carbonate (but not aluminium hydroxide) were found to actually increase the acidity of the stomach. However, all antacids reduced acidity in the lower esophagus, so the net effect on GERD symptoms may still be positive.
- Smoking reduces lower esophageal sphincter competence, thus allowing acid to enter the esophagus.
Sleeping on the left side has been shown to reduce nighttime reflux episodes in patients.
A meta-analysis suggested that elevating the head of the bed is an effective therapy, although this conclusion was only supported by nonrandomized studies. The head of the bed can be elevated by plastic or wooden bed risers that support bed posts or legs, a therapeutic bed wedge pillow, a wedge or an inflatable mattress lifter that fits in between mattress and box spring or a hospital bed with an elevate feature. The height of the elevation is critical and must be at least 6 to 8 inches (15 to 20 cm) to be at least minimally effective to prevent the backflow of gastric fluids. Some innerspring mattresses do not work well when inclined and may cause back pain; some prefer foam mattresses. Some practitioners use higher degrees of incline than provided by the commonly suggested 6 to 8 inches (15 to 20 cm) and claim greater success.
A number of drugs are approved to treat GERD, and are among the most prescribed medication in Western countries. Medical societies recommend that when a doctor and patient decide on a plan for treating GERD long-term with acid-suppression drugs that the lowest possible effective dose be used.
Helicobacter pylori previously named Campylobacter pyloridis, is a Gram-negative, microaerophilic bacterium found in the stomach, has been implicated with GERD and can be easily treated with antibiotics.
- Proton pump inhibitors (such as omeprazole, esomeprazole, pantoprazole, lansoprazole, and rabeprazole) are the most effective in reducing gastric acid secretion. These drugs stop acid secretion at the source of acid production, i.e., the proton pump.
- Gastric H2 receptor blockers (such as ranitidine, famotidine and cimetidine) can reduce gastric secretion of acid. These drugs are technically antihistamines. They relieve complaints in about 50% of all GERD patients. Compared to placebo (which also is associated with symptom improvement), they have a number needed to treat (NNT) of eight (8).
- Antacids before meals or symptomatically after symptoms begin can reduce gastric acidity (increase pH).
- Alginic acid (Gaviscon) may coat the mucosa as well as increase pH and decrease reflux. A meta-analysis of randomized controlled trials suggests alginic acid may be the most effective of non-prescription treatments with a NNT of four.
- Prokinetics strengthen the lower esophageal sphincter (LES) and speed up gastric emptying. Cisapride, a member of this class, was withdrawn from the market for causing long QT syndrome. Reglan (metoclopramide) is a prokinetic with a better side-effect profile.
- Sucralfate (Carafate) is also useful as an adjunct in helping to heal and prevent esophageal damage caused by GERD, however it must be taken several times daily and at least two (2) hours apart from meals and medications.
- Mosapride citrate is a 5-HT4 receptor agonist used outside the United States largely as a therapy for GERD and dyspepsia.
- Baclofen is an agonist of GABAB receptor. In addition to its skeletal muscle relaxant properties, it has also been shown to decrease transient lower esophageal sphincter relaxations at a dose of 10 mg given four times daily. Reductions in esophageal relaxation clinically reduce episodes of reflux.
Clinical trials which compare GERD treatments head-to-head provide physicians with critical information. Unfortunately most pharmaceutical-company sponsored studies are conducted versus placebo and not an active control. However, the DIAMOND has shown rough equivalence of efficacy between a "step-up" approach to therapy (antacids, followed by histamine antagonists, followed by PPIs) and a "step-down" approach (the reverse). The primary endpoint of the study was treatment success after six months, and was achieved for 70% of patients in "step-down" versus 72% of patients in "step-up."
The standard surgical treatment is the Nissen fundoplication. In this procedure the upper part of the stomach is wrapped around the lower esophageal sphincter (LES) to strengthen the sphincter and prevent acid reflux and to repair a hiatal hernia. The procedure is often done laparoscopically. When compared to medical management laparoscopic fundoplication had better results at 1 year. In addition, laparoscopic fundoplication may reduce SF-36 score (quality of life questionnaire) among patients with gastro-esophageal reflux disease as compared to medical management according to a Cochrane systematic review of randomized controlled trials. There were statistically significant improvements in quality of life at 3 months and 1 year after surgery compared to medical therapy, with an SF-36 general health score mean difference of -5.23 in favor of surgery.
An obsolete treatment is vagotomy ("highly selective vagotomy"), the surgical removal of vagus nerve branches that innervate the stomach lining. This treatment has been largely replaced by medication.
Another treatment is transoral incisionless fundoplication (TIF) with the use of a device called Esophyx, which allows doctors to rebuild the valve between the stomach and the esophagus by going through the esophagus.
In 2000 the U.S. Food and Drug Administration (FDA) approved two endoscopic devices to treat chronic heartburn. One system, Endocinch, puts stitches in the LES to create little pleats that help strengthen the muscle. However, long-term results were disappointing, and the device is no longer sold by Bard. Another, the Stretta Procedure, uses electrodes to apply radio frequency energy to the LES. The long-term outcomes of both procedures compared to a Nissen fundoplication are still being determined.
Subsequently the NDO Surgical Plicator was cleared by the FDA for endoscopic GERD treatment. The Plicator creates a plication, or fold, of tissue near the gastroesophageal junction, and fixates the plication with a suture-based implant. The company ceased operations in mid 2008, and the device is no longer on the market.
In pregnancy dietary modifications and lifestyle changes may be attempted but often have little effect. Calcium-based antacids are recommended if these changes are not effective. Aluminum- and magnesium antacids are also safe as is ranitidine.
Infants may see relief with changes in feeding techniques, such as smaller, more frequent feedings, changes in position during feedings, or more frequent burping during feedings. They may also be treated with medicines such as ranitidine.
Every year GERD affects approximately 4.5 per 1000 persons in the United Kingdom and 5.4 per 1000 persons in the United States. It is possible, given the limitations of the relevant studies, that these figures may be larger than estimated. There are no data that support sex predominance with regard to GERD.
In Western populations, the prevalence range for GERD is 10% to 20% of the population. For instance, an estimated 3.4 million to 6.8 million Canadians are GERD sufferers. The prevalence rate of GERD in developed nations is also tightly linked with age, with adults aged 60 to 70 being the most commonly affected. The combination of longer life expectancy and aging populations in the developed world is expected to lead to an increase in GERD prevalence in the years to come.
- ^ DeVault KR, Castell DO (1999). "Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology". Am J Gastroenterol 94 (6): 1434–42. doi:10.1111/j.1572-0241.1999.1123_a.x. PMID 10364004.
- ^ a b c Kahrilas, PJ (2008). "Gastroesophageal Reflux Disease". New England Journal of Medicine. 359 (16): 1700–7. doi:10.1056/NEJMcp0804684. PMC 3058591. PMID 18923172. //www.ncbi.nlm.nih.gov/pmc/articles/PMC3058591/.
- ^ a b Wang KK, Sampliner RE (March 2008). "Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus". Am J Gastroenterol 103 (3): 788–97. doi:10.1111/j.1572-0241.2008.01835.x. PMID 18341497. http://www.acg.gi.org/physicians/guidelines/BarrettsEsophagus08.pdf.
- ^ "Consumer Health Information". Healthlink.mcw.edu. http://healthlink.mcw.edu/article/968784529.html. Retrieved 2009-08-19.
- ^ "Spitting Up in Babies". familydoctor.org. http://familydoctor.org/online/famdocen/home/children/parents/infants/218.html.
- ^ http://en.wikipedia.org/wiki/Baby_colic#Fourth_trimester_theory
- ^ and Barrett's Esophagus. Retrieved on 2009-02-01.
- ^ Numans, ME; Lau, J; de Wit, NJ; Bonis, PA (April 2004). "Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics". Annals of internal medicine 140 (7): 518–27. PMID 15068979. http://www.annals.org/content/140/7/518.full.pdf.
- ^ Diagnosis - Endoscopy. Retrieved on 2009-03-20.
- ^ Mills, S (ed.) 2009.Sternberg's Diagnostic Pathology. 5th Edition. ISBN 978-0-7817-7942-5
- ^ Sontag S (1999). "Defining GERD". Yale J Biol Med 72 (2–3): 69–80. PMC 2579007. PMID 10780568. //www.ncbi.nlm.nih.gov/pmc/articles/PMC2579007/.
- ^ a b c Piesman M, Hwang I, Maydonovitch C, Wong RK (2007). "Nocturnal reflux episodes following the administration of a standardized meal. Does timing matter?". Am J Gastroenterol 102 (10): 2128–34. doi:10.1111/j.1572-0241.2007.01348.x. PMID 17573791.
- ^ Ayazi S, Crookes PF, Peyre CG et al. (2007). "Objective documentation of the link between gastroesophageal reflux disease and obesity". Am J Gastroenterol 102 (S2): 138–9. doi:10.1111/j.1572-0241.2007.01491_1.x. http://www.nature.com/ajg/journal/v102/n2s/full/ajg2007595a.html.
- ^ Ayazi S, Hagen JA, Chan LS et al. (August 2009). "Obesity and Gastroesophageal Reflux: Quantifying the Association Between Body Mass Index, Esophageal Acid Exposure, and Lower Esophageal Sphincter Status in a Large Series of Patients with Reflux Symptoms". J. Gastrointest. Surg. 13 (8): 1440–7. doi:10.1007/s11605-009-0930-7. PMC 2710497. PMID 19475461. //www.ncbi.nlm.nih.gov/pmc/articles/PMC2710497/.
- ^ Morse CA, Quan SF, Mays MZ, Green C, Stephen G, Fass R (2004). "Is there a relationship between obstructive sleep apnea and gastroesophageal reflux disease?". Clin. Gastroenterol. Hepatol. 2 (9): 761–8. doi:10.1016/S1542-3565(04)00347-7. PMID 15354276.
- ^ Kasasbeh A, Kasasbeh E, Krishnaswamy G (2007). "Potential mechanisms connecting asthma, esophageal reflux, and obesity/sleep apnea complex—a hypothetical review". Sleep Med Rev 11 (1): 47–58. doi:10.1016/j.smrv.2006.05.001. PMID 17198758.
- ^ H.J. O'Connor (Feb 1999). "Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management". Aliment Pharmacol Ther 13 (2): 117–27. doi:10.1046/j.1365-2036.1999.00460.x. PMID 10102940.
- ^ El-Omar E, Oien K, Nujuni AE et al. (1997). "Helicobacter pylori infection and chronic gastric acid hyposecretion". Gastroenterology 113 (1): 15–24. doi:10.1016/S0016-5085(97)70075-1. PMID 9207257.
- ^ C.A. Fallone, A.N. Barkun, S. Mayrand, G. Wakil, G. Friedman, A. Szilagyi, C. Wheeler & D. Ross (2004). "There is no difference in the disease severity of gastro-oesophageal reflux disease between patients infected and not infected with Helicobacter pylori". Aliment Pharmacol Ther 20 (7): 761–8. doi:10.1111/j.1365-2036.2004.02171.x. PMID 15379836. http://www3.interscience.wiley.com/cgi-bin/fulltext/118774431/HTMLSTART.
- ^ a b c d e Kaltenbach T, Crockett S, Gerson LB (2006). "Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach". Arch. Intern. Med. 166 (9): 965–71. doi:10.1001/archinte.166.9.965. PMID 16682569.
- ^ a b Khoury, RM; Camacho-Lobato L, Katz PO, Mohiuddin MA, Castell DO (1999). "Influence of spontaneous sleep positions on nighttime recumbent reflux in patients with gastroesophageal reflux disease". Am J Gastroenterol 94 (8): 2069–73. doi:10.1111/j.1572-0241.1999.01279.x. PMID 10445529.
- ^ "Lifestyle Changes to Manage Your Heartburn" WebMD
- ^ Decktor DL, Robinson M, Maton PN, Lanza FL, Gottlieb S (1995). "Effects of Aluminum/Magnesium Hydroxide and Calcium Carbonate on Esophageal and Gastric pH in Subjects with Heartburn". Am J Ther 2 (8): 546–52. doi:10.1097/00045391-199508000-00006. PMID 11854825.
- ^ American Gastroenterological Association, "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation (American Gastroenterological Association), http://choosingwisely.org/wp-content/uploads/2012/04/5things_12_factsheet_AGA.pdf, retrieved August 17, 2012
- ^ Consumer Reports; American Gastroenterological Association (April 2012), "Treating heartburn and GERD: Use Nexium, Prilosec, and related drugs carefully", Choosing Wisely: an initiative of the ABIM Foundation (Consumer Reports), http://consumerhealthchoices.org/wp-content/uploads/2012/05/ChoosingWiselyHeartburnAGA2.pdf, retrieved August 17, 2012
- ^ Kahrilas, P. J.; Shaheen, N. J.; Vaezi, M. F.; Hiltz, S. W.; Black, E.; Modlin, I. M.; Johnson, S. P.; Allen, J. et al. (2008). "American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease". Gastroenterology 135 (4): 1383–1391, 1391.e1–5. doi:10.1053/j.gastro.2008.08.045. PMID 18789939.
- ^ a b Tran T, Lowry A, El-Serag H (2007). "Meta-analysis: the efficacy of over-the-counter gastro-oesophageal reflux disease drugs". Aliment Pharmacol Ther 25 (2): 143–53. doi:10.1111/j.1365-2036.2006.03135.x. PMID 17229239.
- ^ Cash, B.D.; Chey, W.D.. "Role of Serotonergic Agents in Primary Chronic Constipation: Serotonergic Agents and Chronic Constipation". MedScape. p. 4. http://www.medscape.com/viewarticle/518324_4. Retrieved 2009-09-07.
- ^ Fass, Ronnie. "Medical Management of GERD". MedScape. http://www.medscape.org/viewarticle/434528. Retrieved 2011-02-18.
- ^ van Marrewijk CJ, Mujakovic S, Fransen GA, Numans ME, de Wit NJ, Muris JW, van Oijen MG, Jansen JB, Grobbee DE, Knottnerus JA, Laheij RJ (January 2009). "Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial". The Lancet 373 (9659): 215–25. doi:10.1016/S0140-6736(09)60070-2. PMID 19150702.
- ^ Abbas A, Deschamps C, Cassivi SD et al. (2004). "The role of laparoscopic fundoplication in Barrett's esophagus". Annals of Thoracic Surgery 77 (2): 393–6. doi:10.1016/S0003-4975(03)01352-3. PMID 14759403.
- ^ Grant AM, Wileman SM, Ramsay CR et al. (2008). "Minimal access surgery compared with medical management for chronic gastro-oesophageal reflux disease: UK collaborative randomised trial". BMJ 337: a2664. doi:10.1136/bmj.a2664. PMC 2603580. PMID 19074946. //www.ncbi.nlm.nih.gov/pmc/articles/PMC2603580/.
- ^ Wileman, SM; McCann, S; Grant, AM; Krukowski, ZH; Bruce, J; Wileman, Samantha M (2010). Wileman, Samantha M. ed. "Medical versus surgical management for gastro-oesophageal reflux disease (GORD) in adults". Cochrane database of systematic reviews (Online) 3 (3): CD003243. doi:10.1002/14651858.CD003243.pub2. PMID 20238321.
- ^ "New Surgery For Acid Reflux Sufferers". CBS Interactive Inc. January 16, 2009. http://www.cbsnews.com/stories/2009/01/16/health/main4728359.shtml. Retrieved 2009-09-07.
- ^ Mahadevan U, Kane S (July 2006). "American gastroenterological association institute medical position statement on the use of gastrointestinal medications in pregnancy". Gastroenterology 131 (1): 278–82. doi:10.1053/j.gastro.2006.04.048. PMID 16831610.
- ^ http://www.mayoclinic.com/health/infant-acid-reflux/DS00787
- ^ Ruigomez A, Garcia Rodriguez LA, Wallander MA et al. (September 2006). "Comparison of gastro-oesophageal reflux disease and heartburn diagnoses in UK primary care". CMRO 22 (9): 1661–8. doi:10.1185/030079906X120986. PMID 16968569. Lay summary.
- ^ Kotzan J, Wade W, Yu HH (September 2001). "Assessing NSAID prescription use as a predisposing factor for gastroesophageal reflux disease in a Medicaid population". Pharm Res 18 (9): 1367–72. doi:10.1023/A:1013010616496. PMID 11683254. Lay summary.
- ^ Fedorak RN, Veldhuyzen van Zanten S, Bridges R (July 2010). "Canadian Digestive Health Foundation Public Impact Series: Gastroesophageal reflux disease in Canada: Incidence, prevalence, and direct and indirect economic impact". Canadian Journal of Gastroenterology 24 (7): 431–4. PMC 2918483. PMID 20652158. //www.ncbi.nlm.nih.gov/pmc/articles/PMC2918483/. Lay summary.
- Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM, Johnson SP, Allen J, Brill JV (October 2008). "American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease". Gastroenterology 135 (4): 1383–91, 1391.e1–5. doi:10.1053/j.gastro.2008.08.045. PMID 18789939. Lay summary.
- Lichtenstein DR, Cash BD, Davila R, Baron TH, Adler DG, Anderson MA, Dominitz JA, Gan SI, Harrison ME, Ikenberry SO, Qureshi WA, Rajan E, Shen B, Zuckerman MJ, Fanelli RD, VanGuilder T (August 2007). "Role of endoscopy in the management of GERD". Gastrointest. Endosc. 66 (2): 219–24. doi:10.1016/j.gie.2007.05.027. PMID 17643692. Lay summary.
- Hirano I, Richter JE (March 2007). "ACG practice guidelines: esophageal reflux testing". Am J Gastroenterol 102 (3): 668–85. doi:10.1111/j.1572-0241.2006.00936.x. PMID 17335450. http://www.acg.gi.org/physicians/guidelines/EsophagealRefluxTesting.pdf.